Retatrutide

Retatrutide

Retatrutide (LY3437943)

Triple GLP-1/GIP/glucagon agonist

Fat Loss ★ 88
Half-life
~6 days (SubQ)
Cycle
No structured break — long-term maintenance like semaglutide.
Storage
Lyophilized: refrigerated 2-8°C. After reconstitution: 2-8°C, 28 days.
Research
Phase 3 (TRIUMPH program 2024-2025), likely FDA approval in 2026

About

Eli Lilly's triple-agonist peptide that activates GLP-1, GIP and glucagon receptors simultaneously. Phase 3 trials show 24%+ weight loss after 48 weeks — the largest weight loss seen with any GLP-1-class drug to date.

Mechanism

Triple activation: GLP-1 (appetite suppression + insulin), GIP (insulin sensitivity), glucagon (energy expenditure and lipolysis).

Dosage

2 mg
1x per week (4-week titration)
0102030405060708090100

Draw to 50 units on a U-100 insulin syringe

8 mg · 2 mL BAC

Route
Subcutaneous (SubQ)
Duration
Long-term

When to take: Same weekday each week, independent of meals. Best in the morning or evening.

Reconstitution

Vial size (mg): 8 mg · BAC water (mL): 2 mL · Concentration: 4 mg/mL

Can be stored refrigerated after reconstitution for up to 4 weeks.

Benefits

  • Largest weight loss among GLP-1 class drugs
  • Improved glycemic control
  • Increased energy expenditure
  • Cardioprotective effects (preliminary)

Side effects

  • Nausea and vomiting (common initially)
  • Diarrhea and constipation
  • Headache
  • Possible pancreatitis (rare)

Gender notes

Same dose as general protocol. Popular for metabolic syndrome.

Cautions

  • Pregnancy and breastfeeding
  • History of pancreatitis
  • Medullary thyroid carcinoma (MEN2)
  • Severe gastroparesis

Research

Stacks well with

MOTS-cTesamorelin
Add reminder Calculator